Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging

被引:34
|
作者
Hodel, Jerome [1 ,2 ,5 ,7 ]
Outteryck, Olivier [1 ,3 ]
Dubron, Celine [1 ,2 ]
Dutouquet, Bastien [1 ,2 ]
Benadjaoud, Mohamed Amine [8 ]
Duhin, Emeline [1 ,3 ]
Verclytte, Sebastien [4 ]
Zins, Marc [9 ]
Luciani, Alain [6 ,7 ]
Rahmouni, Alain [6 ,7 ]
Pruvo, Jean-Pierre [1 ,2 ]
Vermersch, Patrick [1 ,3 ]
Leclerc, Xavier [1 ,2 ]
机构
[1] Univ Lille, CHU Lille, Lille, France
[2] Hop Roger Salengro, Dept Neuroradiol, Rue Emile Laine, F-59037 Lille, France
[3] Hop Roger Salengro, Dept Neurol, Rue Emile Laine, F-59037 Lille, France
[4] Hop St Philibert, Dept Radiol, Lille, France
[5] Hop Univ Henri Mondor, AP HP, Dept Neuroradiol, Creteil, France
[6] Hop Univ Henri Mondor, AP HP, Dept Med Imaging, Creteil, France
[7] Univ Paris Est Creteil, Fac Med, Creteil, France
[8] CESP Ctr Res Epidemiol & Populat Hlth, INSERM, U1018, Radiat Epidemiol Team, Villejuif, France
[9] Hop St Joseph, Dept Radiol, F-75674 Paris, France
关键词
JC VIRUS-INFECTION; MULTIPLE-SCLEROSIS; PML; DISEASE; PATTERN; PATIENT;
D O I
10.1148/radiol.2015150673
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To determine diagnostic precision with magnetic resonance (MR) imaging of the brain, the most predictive MR imaging features, and the added value of comparison with previous data for the diagnosis of asymptomatic progressive multifocal leukoencephalopathy (PML) associated with natalizumab (NTZ). Materials and Methods: This retrospective study was approved by the institutional review board, and written informed consent was obtained. Eleven consecutive patients with multiple sclerosis (MS) who had received a definitive diagnosis of asymptomatic NTZ-associated PML (NTZ PML, 18 brain lesions) underwent 3-T MR imaging. The control group included 40 patients with MS but without PML who were treated with NTZ. Three readers independently performed blinded analysis of MR images. First, the readers were asked to detect NTZ PML lesions without comparing current images with previously obtained MR imaging data by evaluating MR images for the following features: U fiber and/or cortex involvement, lesion signal intensity and borders, and occurrence of punctate lesions. Second, they reassessed NTZ PML lesions with all the previous MR imaging data available. Diagnostic precision with MR imaging was assessed with and without comparison with previously obtained data. Logistic regression analyses were performed to identify the association of MR imaging features with NTZ PML. Results: Overall interobserver agreement was good (k = 0.76; 95% confidence interval [CI]: 0.71, 0.81). Hyperintensity on diffusion-weighted images and involvement of U fibers were the most predictive features (odds ratio, 33.7; 95% CI: 4.9, 229.7 [P < .0001] and odds ratio, 8.7; 95% CI: 1.2, 61.4 [P = .03], respectively), while punctate lesions were exclusively observed in patients with NTZ PML. Comparison with previous MR imaging data improved specificity of MR imaging for the detection of NTZ PML lesions (from 88% to 100%, P = .05). Conclusion: Recognition of the most predictive imaging features and comparison with previous MR imaging data may facilitate the detection of asymptomatic NTZ PML. (C) RSNA, 2015
引用
收藏
页码:863 / 872
页数:10
相关论文
共 50 条
  • [41] A Case of Natalizumab-associated Progressive Multifocal Leukoencephalopathy—Role for Advanced MRI?
    M. Berghoff
    B. Dassinger
    J. Iwinska-Zelder
    M. Giraldo
    S. Bilgin
    M. Kaps
    E. R. Gizewski
    Clinical Neuroradiology, 2014, 24 : 173 - 176
  • [42] Quantitative electroencephalography supports diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy
    Classen, G.
    Classen, C.
    Bernasconi, C.
    Brandt, C.
    Gold, R.
    Chan, A.
    Hoepner, R.
    JOURNAL OF NEUROVIROLOGY, 2019, 25 (01) : 133 - 136
  • [43] Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations
    van Kempen, Zoe L. E.
    Leurs, Cyra E.
    Vennegoor, Anke
    Wattjes, Mike P.
    Rispens, Theo
    Uitdehaag, Bernard M. J.
    Killestein, Joep
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (07) : 995 - 999
  • [44] Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy
    Tuan Dong-Si
    Sarah Gheuens
    Amy Gangadharan
    Made Wenten
    Jeffrey Philip
    James McIninch
    Shoibal Datta
    Nancy Richert
    Carmen Bozic
    Gary Bloomgren
    Sandra Richman
    Thomas Weber
    David B. Clifford
    Journal of NeuroVirology, 2015, 21 : 637 - 644
  • [45] Overview of Clinical Outcomes in Cases of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
    Gold, Ralf
    Foley, John
    Vermersch, Patrick
    Kappos, Ludwig
    Olsson, Tomas
    Cadavid, Diego
    Bozic, Carmen
    Richman, Sandra
    NEUROLOGY, 2011, 76 (09) : A636 - A636
  • [47] Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy
    Borchardt, Julian
    Berger, Joseph R.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 8 : 145 - 150
  • [48] Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy
    Kinner, Markus
    Prehn, Christian
    Schneider, Ruth
    Schroeder, Christoph
    Kolb, Eva
    Gold, Ralf
    Hoepner, Robert
    Chan, Andew
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (03) : 921 - 927
  • [49] Natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients: survival and functional outcome when asymptomatic at diagnosis
    Dong-Si, T.
    Richman, S.
    Bloomgren, G.
    Wenten, M.
    Philip, J.
    Datta, S.
    McIninch, J.
    Bozic, C.
    Ticho, B.
    Richert, N.
    JOURNAL OF NEUROLOGY, 2013, 260 : S70 - S71
  • [50] Determinants of clinical outcomes for patients with Natalizumab-associated progressive multifocal leukoencephalopathy
    Kappos, L.
    Mcguigan, C.
    Derfuss, T.
    Giovannoni, G.
    Oh, J.
    Ren, Z.
    McCarthy, K.
    Chang, I.
    Campbell, N.
    Ho, P. -R.
    Mason, L.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 19 - 20